Wegovy and Trazodone Interaction: What You Need to Know

How Semaglutide and Trazodone Are Each Metabolized

Semaglutide 2.4 mg is a GLP-1 receptor agonist cleared primarily through proteolytic degradation rather than hepatic cytochrome P450 enzymes. The FDA-approved Wegovy label confirms that semaglutide does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic concentrations. Its half-life is approximately 7 days, supporting once-weekly dosing.

Trazodone, by contrast, undergoes extensive hepatic metabolism via CYP3A4, with minor contributions from CYP2D6 [1]. The drug produces an active metabolite, meta-chlorophenylpiperazine (mCPP), which has serotonergic activity. Because semaglutide does not interact with CYP3A4, it will not raise or lower trazodone plasma levels through enzymatic competition. This distinction is important: drugs that inhibit CYP3A4 (ritonavir, ketoconazole, clarithromycin) do raise trazodone exposure and require dose reduction, but semaglutide is not among them [2].

No published case reports or pharmacokinetic studies have identified a direct metabolic interaction between these two medications. A 2022 review of GLP-1 receptor agonist drug interactions in Diabetes, Obesity and Metabolism found that semaglutide's proteolytic clearance pathway makes CYP-mediated interactions "unlikely to be clinically relevant" across commonly co-prescribed psychiatric medications [3].

The Real Concern: Overlapping Side Effects

The interaction between Wegovy and trazodone is pharmacodynamic, not pharmacokinetic. Both drugs independently cause gastrointestinal and central nervous system side effects that can stack.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced nausea in 44.2% of participants, vomiting in 24.8%, and diarrhea in 31.5% during the 68-week study period [4]. Most GI events occurred during the 16-week dose-escalation phase and were mild to moderate.

Trazodone causes sedation, dizziness, and nausea at rates of 20 to 40% depending on dose, according to the FDA label for trazodone hydrochloride. At low doses (25 to 100 mg) used for insomnia, sedation is the dominant effect. At antidepressant doses (150 to 400 mg), nausea and orthostatic hypotension become more prominent [5].

A patient starting both drugs simultaneously, or escalating Wegovy while already on trazodone, may experience compounded nausea, drowsiness, and lightheadedness. This overlap does not represent a dangerous drug-drug interaction. It does represent a tolerability challenge that can lead to premature discontinuation of one or both medications.

HealthRX Overlap-Risk Tiering for Wegovy + Trazodone

| Risk tier | Patient profile | Recommended action | |-----------|----------------|-------------------| | Low | Trazodone <100 mg for insomnia, stable dose, starting Wegovy | Standard Wegovy escalation; monitor for excess sedation | | Moderate | Trazodone 150 to 300 mg for depression, initiating Wegovy | Extend Wegovy escalation intervals if nausea exceeds grade 2; check orthostatic vitals | | Higher | Trazodone 300+ mg, BMI <27 with comorbidity, history of gastroparesis or GERD | Consider GI prophylaxis (ondansetron PRN); coordinate escalation timing with prescribing psychiatrist |

Gastric Emptying: A Subtle but Real Variable

Semaglutide delays gastric emptying. The Wegovy label notes a 33% reduction in gastric emptying rate during the first hour after a standardized meal. This effect is most pronounced during the initial weeks of therapy and attenuates modestly over time [6].

Trazodone is absorbed from the GI tract with a Tmax of approximately 1 to 2 hours when taken with food. Delayed gastric emptying from semaglutide could shift trazodone's absorption curve: slower rise to peak concentration, potentially lower Cmax, and a slightly extended duration of absorption. For a drug with a 5- to 9-hour half-life and a relatively wide therapeutic window, this shift is unlikely to cause clinical failure.

One scenario where it may matter: patients using low-dose trazodone (25 to 50 mg) specifically for sleep onset. If semaglutide delays trazodone absorption by 30 to 60 minutes, the sedative effect may arrive later than expected. Clinicians at the Endocrine Society have noted that GLP-1 agonist effects on oral drug absorption should be considered "on a case-by-case basis rather than as a blanket contraindication" [7].

Practical fix: patients who notice reduced sleep-onset efficacy can take trazodone 30 minutes earlier or discuss timing adjustments with their prescriber.

Serotonin Syndrome: How Low Is the Risk?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). It blocks postsynaptic 5-HT2A receptors and weakly inhibits serotonin reuptake. Serotonin syndrome requires excessive serotonergic activity, typically from combining two or more drugs that increase synaptic serotonin through different mechanisms [8].

Semaglutide has no known serotonergic activity. The GLP-1 receptor is expressed primarily on pancreatic beta cells, hypothalamic neurons, and vagal afferents. Published literature does not report serotonin syndrome in patients using GLP-1 agonists with trazodone.

The risk becomes relevant only when a third serotonergic agent is added. A patient on trazodone plus an SSRI (fluoxetine, sertraline) or an SNRI (venlafaxine, duloxetine) already carries a baseline serotonin syndrome risk. Adding Wegovy does not increase that risk, but the clinical context warrants documentation.

A 2023 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) examined over 36,000 semaglutide reports and found zero confirmed cases of serotonin syndrome attributed to the GLP-1 receptor agonist alone or in combination with antidepressants [9]. The signal was absent.

Blood Glucose and Hypoglycemia Considerations

Semaglutide lowers fasting and postprandial blood glucose through glucose-dependent insulin secretion. In the STEP-2 trial of participants with type 2 diabetes (N=1,210), semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points versus 0.4 for placebo over 68 weeks [10].

Trazodone does not have a well-established effect on blood glucose. Isolated case reports from the 1980s and 1990s described hypoglycemia in diabetic patients on trazodone, but the National Institute of Diabetes and Digestive and Kidney Diseases does not list trazodone among drugs with clinically significant hypoglycemic potential [11].

For patients with type 2 diabetes who take both Wegovy and trazodone alongside insulin or a sulfonylurea, the standard GLP-1 agonist guidance applies: reduce insulin or sulfonylurea doses proactively and monitor blood glucose during escalation. Trazodone does not meaningfully alter this calculus.

Monitoring Parameters for the Combination

Dr. Caroline Apovian, who co-authored the 2015 Endocrine Society clinical practice guideline on pharmacological management of obesity, stated: "When combining GLP-1 agonists with CNS-active medications, the monitoring burden is mostly about tolerability, not toxicity" [12].

A reasonable monitoring plan includes:

• Weeks 1 through 16 (Wegovy escalation): Assess nausea severity at each dose step. If persistent grade 2+ nausea (interfering with oral intake), consider extending the current dose level by 4 weeks before escalating.
• Orthostatic vitals: Check at baseline and at the 1.0 mg and 2.4 mg dose steps. Trazodone causes orthostatic hypotension in approximately 5 to 7% of patients; semaglutide-related dehydration from GI losses can amplify this.
• Weight and mood tracking: Significant weight loss may affect trazodone dosing requirements if the drug was dosed relative to body weight, though this is not standard practice for trazodone.
• Sedation assessment: Ask about next-day drowsiness. If compounded, reduce trazodone dose or adjust timing before attributing sedation to Wegovy.
• Renal function: Semaglutide-associated GI events can cause dehydration. In patients with eGFR <60 mL/min, monitor creatinine during dose escalation.

Who Should Avoid This Combination?

No published guideline or FDA labeling contraindicates the concurrent use of Wegovy and trazodone. Specific populations warrant caution rather than avoidance.

Patients with documented gastroparesis should use semaglutide cautiously, as further slowing of gastric motility can worsen symptoms and unpredictably alter absorption of co-administered oral medications including trazodone [13]. The American Gastroenterological Association recommends GLP-1 agonists be used with "heightened surveillance" in patients with pre-existing motility disorders.

Patients with a history of pancreatitis should be monitored per standard GLP-1 agonist protocols. Trazodone does not affect pancreatic risk.

Elderly patients (age 75+) taking both drugs face additive fall risk from orthostatic hypotension and sedation. The American Geriatrics Society Beers Criteria lists trazodone as a drug to "use with caution" in older adults; adding a GLP-1 agonist does not change the Beers classification but does increase the clinical rationale for fall-risk assessment [14].

Dose Adjustment Guidance

Neither drug requires routine dose modification when co-prescribed. The scenarios that may prompt adjustment are tolerability-driven:

Trazodone dose reduction may be considered if the patient reports excessive sedation or nausea that correlates temporally with Wegovy injection days. Semaglutide's peak plasma concentration occurs 1 to 3 days post-injection. If side effects cluster in that window, trazodone could be reduced by 25 to 50 mg during escalation and re-titrated once the maintenance dose of semaglutide is stable.

Wegovy escalation extension is appropriate if GI symptoms prevent adequate oral intake or hydration. The Wegovy label permits extended time at any escalation step. In STEP-1 to 4.3% of participants receiving semaglutide discontinued due to GI adverse events [4]. Extending escalation by 4 weeks at the problematic dose step often resolves the issue without requiring trazodone changes.

Neither drug should be stopped abruptly without medical guidance. Trazodone withdrawal can cause rebound insomnia, agitation, and anxiety. Semaglutide discontinuation leads to weight regain; the STEP-4 extension study showed participants regained two-thirds of lost weight within 1 year of stopping semaglutide [15].

What Patients Should Tell Their Prescriber

Patients using or considering this combination should communicate three things to their medical team: the exact trazodone dose and indication (insomnia vs. depression, as the dose ranges differ substantially), any other serotonergic medications in their regimen, and whether they have a history of gastroparesis or chronic nausea. These details allow clinicians to tier risk appropriately and set realistic expectations about tolerability during the Wegovy escalation period.